A common polymorphism in the Intelectin-1 gene influences mucus plugging in severe asthma

Area of Science:

• Immunology
• Molecular Biology
• Respiratory Medicine

Background:

• Type 2 (T2) inflammation in severe asthma causes pathological mucus production and airway mucus plugging.
• The precise molecular mechanisms driving mucus hypersecretion in asthma remain incompletely understood.

Purpose of the Study:

• To investigate the role and clinical significance of intelectin-1 (ITLN-1) in the development of pathological airway mucus in asthma.
• To identify potential biomarkers and therapeutic targets for mucus obstruction in asthma.

Main Methods:

• Analysis of human airway epithelial cells stimulated with interleukin-13 (IL-13).
• Investigation of ITLN-1 protein binding to MUC5AC mucin.
• Assessment of ITLN-1 expression in nasal airway brushings from T2-high and T2-low asthmatic children.
• Evaluation of a genetic variant's impact on ITLN-1 levels and mucus plugging.

Main Results:

• Interleukin-13 (IL-13) induces ITLN1 gene expression in MUC5AC+ mucus secretory cells.
• ITLN-1 protein is a component of IL-13-induced mucus and binds to the MUC5AC mucin.
• Deletion of ITLN-1 partially reverses IL-13-induced mucostasis (mucus stasis).
• ITLN1 is highly expressed in T2-high asthmatics compared to T2-low children.
• A protective genetic variant significantly reduces ITLN-1 expression and mucus plugging in T2-high asthma.

Conclusions:

• Intelectin-1 (ITLN-1) plays a critical role in mediating pathological mucus production in severe asthma.
• ITLN-1 is a potential biomarker for T2-high asthma and mucus plugging.
• Targeting ITLN-1 pathways may offer a novel therapeutic strategy for managing airway mucus obstruction in asthma.